openPR Logo
Press release

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

12-29-2016 01:13 PM CET | Health & Medicine

Press release from: Anti-hypertensive Therapeutics in Asia-Pacific Markets

ResearchMoz added Latest Research Report titled " Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline " to it's Large Report database.

Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.

Hypertension itself does not manifest any symptoms, but direct damage can occur to various organs due to high blood pressure. In cases of hypertensive emergency (where blood pressure is higher than 180/110mmHg) patients have reported headaches, breathlessness or malaise due to heart failure and kidney failure. Whether symptomatic or asymptomatic, hypertension requires attention and appropriate changes in lifestyle or medical treatment.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=903617

The marketed products landscape for hypertension comprises a wide range of treatment options, which includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, renin inhibitors, and diuretics. These are used both as monotherapy and combination therapy (including fixed-dose combinations), and the proportion of patients treated using the various therapy approaches varies from country to country.

The high prevalence of the disease is a substantial contributor to healthcare costs and is a major cause of morbidity. However, awareness of hypertension is low among physicians, patients, and the public, leading to a high level of undiagnosed and untreated cases.

Scope

The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
Will generics continue to dominate treatment?
How do the elderly populations and their associated risk factors affect prevalence?
What effect will the patent expirations of currently branded therapies have on market value?

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.5 Diagnosis 13
2.5.1 Office or Clinic Blood Pressure Monitoring 14
2.5.2 Automated Office Blood Pressure Measurement 14
2.5.3 Ambulatory Blood Pressure Monitoring 15
2.5.4 Home Blood Pressure Monitoring 15
2.5.5 Miscellaneous Methods 15
2.5.6 Diagnosis of Target Organ Damage 15
2.5.7 Diagnosis of Hypertension in Pregnancy 15
2.6 Prognosis 16
2.7 Disease Stage 17
2.8 Treatment Options 17
2.8.1 Treatment Algorithm 17
2.8.2 Pharmacological Treatment 18
2.8.3 Non-pharmacological Treatment 22

3 Marketed Products 24
3.1 Angiotensin II Receptor Antagonists 24
3.1.1 Losartan - Merck & Co 24
3.1.2 Olmesartan - Daiichi Sankyo 26
3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo 27
3.1.4 Valsartan - Novartis 28

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline here

News-ID: 402676 • Views: 260

More Releases for Hypertension

4th International Conference on Hypertension & Healthcare
We take the privilege of hosting International Hypertension meetings worldwide and very excited to expand to 4th International Conference on Hypertension & Healthcare to be held in beautiful city Zurich, Switzerland in the month of September 10th- 11th, 2018. As with the three meetings, the Hypertension 2018 will be on high-level updates, debates, hot topics and future research directions in the areas of Cardiology, cardiovascular diseases, Pulmonary Hypertension, Hypertension &
Global Pulmonary Arterial Hypertension Market to 2024
Global Pulmonary Arterial Hypertension (PAH) market was valued at $5.0bn in 2015 and is forecast to grow at a modest 6.0% CAGR between 2015 and 2024, to result in 2024 global sales of $9.0bn. PAH is broadly split into two classes, primary or secondary. Primary pulmonary hypertension (PPH) refers to pulmonary hypertension occurring without an identifiable cause. Secondary pulmonary arterial hypertension (PAH) occurs in association with some other identifiable medical condition.
Hypertension: Often unnoticed, always a risk
Vital mushrooms provide a valuable contribution in the prevention and therapy of hypertension Hypertension is considered one of the greatest health problems of the modern age. In the United Kingdom alone, according to data from the NHS, about 12,5 million people - almost every fourth - are affected. The great danger: Although hypertension can cause further serious diseases, many sufferers do not suspect their hypertension. They feel well and have
Ocular Hypertension-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Ocular Hypertension-Pipeline Review H2 2017” this report provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape. Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include
Ocular Hypertension - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Ocular Hypertension - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2017, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape. Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous
Renal Hypertension: Diagnosis & Treatment
“Hypertension & Cardiovascular disease after Kidney Transplantation” is one of the workshops to be conducted by Dr. Hossein Tabriziani of Loma Linda University, USA under the session ‘Renal Hypertension’ at the meeting 2nd International Conference on Hypertension & Healthcare which is going to be held at Amsterdam, Netherlands during September 11-13, 2017. High blood pressure is a leading cause of kidney disease and kidney failure ESRD (end stage renal disease). Hypertension